The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 study of neoadjuvant lenvatinib in locally advanced invasive thyroid cancer.
 
Amr Hesham Abdelhamid Ahmed
No Relationships to Disclose
 
Marika D. Russell
No Relationships to Disclose
 
Natalia Kyriazidis
No Relationships to Disclose
 
Amanda Silver Karcioglu
No Relationships to Disclose
 
Eric Jeffrey Sherman
Consulting or Advisory Role - Blueprint Medicines; Eisai; Exelixis; Lilly; UpToDate
Research Funding - HUTCHMED (Inst); Lilly (Inst); Novartis (Inst); Plexxikon (Inst); Regeneron (Inst)
 
Alan Loh Ho
Stock and Other Ownership Interests - Rgenta
Honoraria - Endocrine Society; Physicans' Education Resource
Consulting or Advisory Role - AffyImmune Therapeutics; Ayala Pharmaceuticals; Cellestia Biotech; Eisai; Eisai; Elevar Therapeutics; Exelixis; ExpertConnect; InxMed; Kura Oncology; Merck; Prelude Therapeutics; Remix Therapeutics; Rgenta
Research Funding - Astellas Pharma; AstraZeneca; Ayala Pharmaceuticals; Bayer; Bayer; Bristol-Myers Squibb; Eisai; Elevar Therapeutics; Elevar Therapeutics; Genentech/Roche; Kura Oncology; Merck; Novartis
Patents, Royalties, Other Intellectual Property - LESIONAL DOSIMETRY METHODS FOR TAILORING TARGETED RADIOTHERAPY IN
 
James A Fagin
Research Funding - Eisai (Inst)
 
Richard J. Wong
No Relationships to Disclose
 
Naifa Lamki Busaidy
Honoraria - Eisai; Exelixis
Consulting or Advisory Role - Eisai; Loxo
Research Funding - GlaxoSmithKline/Novartis
 
Mark E. Zafereo
Research Funding - Lilly (Inst); Merck (Inst)
 
Peter Sadow
No Relationships to Disclose
 
Jong Chul Park
Consulting or Advisory Role - GC Cell; Gene Medicine; MitoImmune; Selecxine
 
Lori J. Wirth
Consulting or Advisory Role - Bayer; Coherus Biosciences; Curie Therapeutics; Eisai; Exelixis; Lilly; Merck; METIS Precision Medicine; Morphic Therapeutic; Tome Biosciences
Research Funding - Checkmate Pharmaceuticals (Inst); Eisai (Inst); Lilly (Inst); Novartis (Inst)
Expert Testimony - Eisai
Other Relationship - PDS Biotechnology
 
Gregory W. Randolph
Research Funding - Eisai (Inst); Fluoptics (Inst); Medtronic (Inst)
Other Relationship - American College of Surgeons; American Head and Neck Society (AHNS); International Thyroid Oncology Group; World Congress on Thyroid Cancer (WCTC)